84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]許京華,李東升,李記天.健脾補(bǔ)腎中藥對(duì)惡性骨腫瘤化療后骨髓抑制患者外周血象的影響[J].中醫(yī)正骨,2021,33(04):38-43.
　XU Jinghua,LI Dongsheng,LI Jitian.Effects of Jianpi Bushen(健脾補(bǔ)腎)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(04):38-43.
點(diǎn)擊復(fù)制

健脾補(bǔ)腎中藥對(duì)惡性骨腫瘤化療后骨髓抑制患者外周血象的影響()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期數(shù):
2021年04期
頁(yè)碼:
38-43
欄目:
臨床研究
出版日期:
2021-04-20

文章信息/Info

Title:
Effects of Jianpi Bushen(健脾補(bǔ)腎)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors
作者:
許京華; 李東升; 李記天
(河南省洛陽(yáng)正骨醫(yī)院/河南省骨科醫(yī)院,河南 鄭州 450016)
Author(s):
XU Jinghua; LI Dongsheng; LI Jitian
Luoyang Orthopedic-Traumatological Hospital,Zhengzhou 450016,Henan,China
關(guān)鍵詞:
骨腫瘤;  抗腫瘤聯(lián)合化療方案;  骨髓抑制;  健脾;  補(bǔ)腎;  中藥療法;  骨肉瘤;  肉瘤; Ewing;  組織細(xì)胞瘤; 惡性纖維;  轉(zhuǎn)移癌
Keywords:
bone neoplasms;  antineoplastic combined chemotherapy protocols;  marrow suppression;  STRENGTHENING SPLEEN;  REINFORCING KIDNEY;  DRUG THERAPY(TCD);  osteosarcoma;  sarcoma; Ewing;  histiocytoma; malignant fibrous;  metastatic carcinoma
摘要:
目的:觀(guān)察健脾補(bǔ)腎中藥對(duì)惡性骨腫瘤化療后骨髓抑制患者外周血象的影響。方法:將符合要求的60例惡性骨腫瘤化療后骨髓抑制患者隨機(jī)分為2組,每組30例。聯(lián)合治療組采用健脾補(bǔ)腎中藥口服聯(lián)合重組人粒細(xì)胞集落刺激因子皮下注射治療,單純西藥組采用重組人粒細(xì)胞集落刺激因子皮下注射治療; 均連續(xù)治療7 d為1個(gè)療程,共治療1個(gè)療程。比較2組患者治療前后外周血液中白細(xì)胞計(jì)數(shù)、血紅蛋白含量及血小板計(jì)數(shù),并評(píng)估白細(xì)胞、血紅蛋白及血小板抑制程度。治療結(jié)束1周后,評(píng)價(jià)患者臨床癥狀改善情況及生活質(zhì)量。結(jié)果:①白細(xì)胞計(jì)數(shù)。治療前2組患者的白細(xì)胞計(jì)數(shù)比較,差異無(wú)統(tǒng)計(jì)學(xué)意義[(3.28±0.64)×109個(gè)·L-1,(3.19±0.76)×109個(gè)·L-1,t=0.566,P=0.576]; 治療結(jié)束1周后,2組患者的白細(xì)胞計(jì)數(shù)均高于治療前(t=-6.606,P=0.000; t=-3.583,P=0.000),且聯(lián)合治療組患者的白細(xì)胞計(jì)數(shù)高于單純西藥組[(8.68±1.75)×109個(gè)·L-1,(4.63±1.20)×109個(gè)·L-1,t=10.954,P=0.000]。②血紅蛋白含量。治療前2組患者的血紅蛋白含量比較,差異無(wú)統(tǒng)計(jì)學(xué)意義[(112.47±10.05)g·L-1,(108.63±9.67)g·L-1,t=-1.941,P=0.062]; 治療結(jié)束1周后,2組患者的血紅蛋白含量均高于治療前(t=-11.750,P=0.000; t=-5.695,P=0.000),且聯(lián)合治療組患者的血紅蛋白含量高于單純西藥組[(140.83±17.36)g·L-1,(126.87±15.56)g·L-1,t=4.331,P=0.000]。③血小板計(jì)數(shù)。治療前2組患者的血小板計(jì)數(shù)比較,差異無(wú)統(tǒng)計(jì)學(xué)意義[(121.10±23.51)×109個(gè)·L-1,(126.90±30.52)×109個(gè)·L-1,t=-1.250,P=0.221]; 治療結(jié)束1周后,2組患者的血小板計(jì)數(shù)均高于治療前(t=-12.528,P=0.000; t=-5.846,P=0.000),且聯(lián)合治療組患者的血小板計(jì)數(shù)高于單純西藥組[(224.23±60.28)×109個(gè)·L-1,(187.70±55.89)×109個(gè)·L-1,t=2.741,P=0.010]。④白細(xì)胞抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度9例、Ⅰ度11例、Ⅱ度7例、Ⅲ度3例,單純西藥組0度4例、Ⅰ度7例、Ⅱ度8例、Ⅲ度6例、Ⅳ度5例; 聯(lián)合治療組患者的白細(xì)胞抑制程度優(yōu)于單純西藥組(Z=-2.717,P=0.007)。⑤血紅蛋白抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度8例、Ⅰ度10例、Ⅱ度12例,單純西藥組0度3例、Ⅰ度10例、Ⅱ度6例、Ⅲ度6例、Ⅳ度5例; 聯(lián)合治療組患者的血紅蛋白抑制程度優(yōu)于單純西藥組(Z=-2.547,P=0.011)。⑥血小板抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度11例、Ⅰ度13例、Ⅱ度4例、Ⅲ度2例,單純西藥組0度8例、Ⅰ度7例、Ⅱ度8例、Ⅲ度4例、Ⅳ度3例; 聯(lián)合治療組患者的血小板抑制程度優(yōu)于單純西藥組(Z=-2.009,P=0.045)。⑦臨床癥狀改善情況。治療結(jié)束1周后,聯(lián)合治療組顯著改善13例、部分改善14例、無(wú)效3例,單純西藥組顯著改善7例、部分改善12例、無(wú)效11例; 聯(lián)合治療組患者的臨床癥狀改善情況優(yōu)于單純西藥組(Z=-2.363,P=0.018)。⑧生活質(zhì)量。治療結(jié)束1周后,聯(lián)合治療組改善16例、穩(wěn)定10例、降低4例,單純西藥組改善9例、穩(wěn)定8例、降低13例; 聯(lián)合治療組患者的生活質(zhì)量高于單純西藥組(Z=-2.430,P=0.015)。⑨其他。治療過(guò)程中,單純西藥組6例應(yīng)用促紅細(xì)胞生成素、3例輸注血小板,聯(lián)合治療組無(wú)1例采取上述措施。結(jié)論:對(duì)于惡性骨腫瘤化療后骨髓抑制患者,在采用重組人粒細(xì)胞集落刺激因子皮下注射治療的基礎(chǔ)上,應(yīng)用健脾補(bǔ)腎中藥口服治療,可以增加外周血液中白細(xì)胞計(jì)數(shù)、血紅蛋白含量及血小板計(jì)數(shù),減輕骨髓抑制程度,有利于改善臨床癥狀、提高生活質(zhì)量,其療效優(yōu)于單純采用重組人粒細(xì)胞集落刺激因子皮下注射治療。
Abstract:
To observe the effects of Jianpi Bushen(健脾補(bǔ)腎,JPBS)traditional Chinese medicine(TCM)on peripheral hemogram of patients with myelosuppression after chemotherapy for treatment of malignant bone tumors.Methods:Sixty patients with myelosuppression after chemotherapy for malignant bone tumors were enrolled in the study and were randomly divided into 2 groups,30 cases in each group.The patients were treated with combination therapy of subcutaneous injection of recombinant human granulocyte colony-stimulating factor(rhG-CSF)and oral application of JPBS TCM(combination therapy group)and monotherapy of subcutaneous injection of rhG-CSF(monotherapy group)respectively for one course of treatment,consecutive 7 days for each course.The white blood cell(WBC)counts,hemoglobin(HGB)contents and platelet counts in peripheral blood were recorded and compared between pretreatment and posttreatment and between the 2 groups,and the inhibition degrees of WBC,HGB and platelet were evaluated.Moreover,the improvement of clinical symptoms and life quality of patients in the 2 groups were evaluated at 1 week after the end of the treatment.Results:There was no statistical difference in WBC counts between the 2 groups before the treatment(3.28±0.64 vs 3.19±0.76 ×10(9)cells/L,t=0.566,P=0.576).The WBC counts were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-6.606,P=0.000; t=-3.583,P=0.000),and were higher in combination therapy group compared to monotherapy group(8.68±1.75 vs 4.63±1.20 ×10(9)cells/L,t=10.954,P=0.000).There was no statistical difference in HGB contents between the 2 groups before the treatment(112.47±10.05 vs 108.63±9.67 g/L,t=-1.941,P=0.062).The HGB contents were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-11.750,P=0.000; t=-5.695,P=0.000),and were higher in combination therapy group compared to monotherapy group(140.83±17.36 vs 126.87±15.56 g/L,t=4.331,P=0.000)...

參考文獻(xiàn)/References:

[1] 張劍峰,劉寬榮.骨惡性腫瘤36例手術(shù)治療臨床分析[J].山西醫(yī)藥雜志,2015,44(1):80-82.
[2] 李建強(qiáng),孫虹斐,靳宇,等.補(bǔ)腎益精湯聯(lián)合化療預(yù)防腫瘤患者骨髓抑制的作用及對(duì)血清G-CSF、IL-3水平的影響[J].現(xiàn)代中西醫(yī)結(jié)合雜志,2017,26(33):3708-3710.
[3] 王和鳴,黃桂成.中醫(yī)骨傷科學(xué)[M].3版.北京:中國(guó)中醫(yī)藥出版社,2012:377-378.
[4] 丁聚賢,謝興文,許偉,等.中醫(yī)藥在骨肉瘤放化療中的作用研究進(jìn)展[J].中醫(yī)正骨,2018,30(5):43-46.
[5] 中華醫(yī)學(xué)會(huì)骨科學(xué)分會(huì)骨腫瘤學(xué)組.四肢骨腫瘤保肢治療指南[J].中華骨科雜志,2019,39(1):1-9.
[6] 周際昌.實(shí)用腫瘤內(nèi)科學(xué)[M].2版.北京:人民衛(wèi)生出版社,2003:537-555.
[7] 周仲瑛.中醫(yī)內(nèi)科學(xué)[M].北京:中國(guó)中醫(yī)藥出版社,2017:120-125.
[8] SCHAG C C,HEINRICH R L,GANZ P A.Karnofsky performance status revisited:reliability,and guidelines[J].J Clin Oncol,1984,2(3):187-193.
[9] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[10] CHOI Y Y,KIM J Y,YANG S O.PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions[J].Semin Musculoskelet Radiol,2014,18(2):133-148.
[11] NIU X,XU H,INWARDS C Y,et al.Primary bone tumors:epidemio-logic comparison of 9200 patients treated at Beijing Ji Shui Tan Hospital,Beijing,China,with 10165 patients at Mayo Clinic,Rochester,Minnesota[J].Arch Pathol Lab Med,2015,139(9):1149-1155.
[12] 劉宏杰,張寧,李凌云,等.甲磺酸阿帕替尼三線(xiàn)及以上治療晚期惡性腫瘤52例療效觀(guān)察[J].皖南醫(yī)學(xué)院學(xué)報(bào),2020,39(3):242-245.
[13] 趙秀蘭,張星星,鄭寰宇,等.HIF相關(guān)信號(hào)轉(zhuǎn)導(dǎo)通路因子在宮頸癌中的研究進(jìn)展[J].河北醫(yī)科大學(xué)學(xué)報(bào),2018,39(11):1360-1364.
[14] 王國(guó)華,劉鳳玲,張振山,等.參一膠囊聯(lián)合化療治療晚期非小細(xì)胞肺癌療效觀(guān)察與血清MMP-9及TIMP-1變化[J].現(xiàn)代腫瘤醫(yī)學(xué),2017,25(6):896-901.
[15] 元建華,李建旺,張曙波,等.吉西他濱聯(lián)合替吉奧治療鉑類(lèi)方案化療失敗晚期鼻咽癌患者臨床觀(guān)察[J].中華腫瘤防治雜志,2019,26(3):170-174.
[16] HOU B,LIU R,QIN Z,et al.Oral Chinese herbal Medicine as an adjuvant treatment forchemotherapy,or radiotherapy,induced myelosuppression:a systematic review and Meta analysis of randomized controlled trials[J].Evid Based Complement Alternat Med,2017,2017(5):1-13.
[17] 顧玉蘭.粒細(xì)胞集落刺激因子在化療患者中的應(yīng)用調(diào)查[J].中國(guó)癌癥防治雜志,2014,6(2):177-180.
[18] 陳丹,陳理.中醫(yī)藥防治化療后骨髓抑制的研究進(jìn)展[J].江蘇中醫(yī)藥,2012,44(7):76-77.
[19] 章偉,趙林林,陳立偉,等.惡性腫瘤化療后骨髓抑制的中醫(yī)藥防治進(jìn)展[J].四川中醫(yī),2014,32(6):179-182.
[20] 侯天將,尚靜,由鳳鳴,等.化療所致骨髓抑制的中醫(yī)病機(jī)要素及臨床治療分析[J].云南中醫(yī)中藥雜志,2016,37(9):31-33.
[21] 王茜,竇永起.化療后骨髓抑制的中藥防治研究進(jìn)展[J].現(xiàn)代醫(yī)藥衛(wèi)生,2013,29(14):2141-2143.
[22] 陶靈佳,任建琳,季青,等.健脾補(bǔ)腎復(fù)方治療大腸癌靶點(diǎn)的網(wǎng)絡(luò)藥理學(xué)研究[J].中華中醫(yī)藥雜志,2017,32(4):1772-1774.
[23] 孫政華,邵晶,郭玫.黨參化學(xué)成分及藥理作用研究進(jìn)展[J].安徽農(nóng)業(yè)科學(xué),2015,43(33):174-176.
[24] 劉爽.黃芪藥理作用的研究進(jìn)展[J].北方藥學(xué),2015,12(12):95-96.
[25] 劉醫(yī)輝,楊世英,馬偉林,等.當(dāng)歸藥理作用的研究進(jìn)展[J].中國(guó)當(dāng)代醫(yī)藥,2014,21(22):192-193.
[26] 祝燁.人參、黃芪、當(dāng)歸對(duì)血發(fā)生的影響[J].成都中醫(yī)藥大學(xué)學(xué)報(bào),2000,23(3):55-56.
[27] 芮鑫淼,錢(qián)佳誠(chéng),李永峰,等.健脾補(bǔ)腎法治療放化療后骨髓抑制研究進(jìn)展[J].浙江中西醫(yī)結(jié)合雜志,2019,29(7):606-608.

相似文獻(xiàn)/References:

[1]朱麗英,胡春艷,孟苗,等.唑來(lái)膦酸靜脈滴注聯(lián)合華蟾素膠囊口服治療轉(zhuǎn)移性骨腫瘤[J].中醫(yī)正骨,2017,29(07):55.
[2]易春智,藍(lán)鋆,李若愚,等.冷凍消融術(shù)在骨與軟組織腫瘤治療中的應(yīng)用[J].中醫(yī)正骨,2017,29(09):57.
[3]忻岳軍,陳天亮,尹彬彬.基于CT周?chē)窠?jīng)重建圖像判斷骨和軟組織腫瘤與鄰近神經(jīng)的關(guān)系[J].中醫(yī)正骨,2021,33(10):41.

更新日期/Last Update: 1900-01-01